Therapeutic Strategy with Direct Oral Anticoagulants and Antiaggregant Drugs in Ischemic Heart Disease

Completed

• Conditions: Atrial Fibrillation

• Registration Number: NCT06239402
• Lead Sponsor: Istituti Clinici Scientifici Maugeri SpA

Brief Summary

The study aims to depict the actual prescription patterns employed in clinical practice of patients affected by non-valvular atrial fibrillation undergoing percutaneous coronary intervention (i.e. with a therapeutic indication for dual or triple antithrombotic therapy) and to analyze the outcomes of therapeutic decisions, focusing on mortality, hemorrhagic events, and ischemic events,

Detailed Description

The combination of warfarin, aspirin, and clopidogrel represented the standard antithrombotic therapeutic strategy for patients with atrial fibrillation and suffering from acute coronary syndrome and/or undergoing percutaneous coronary intervention.

Current guidelines and clinical practice guides suggest the use of triple or dual antithrombotic therapy after a careful evaluation of the patient's hemorrhagic and thrombotic profile, without however providing indications with recommendation class I. It is not known what treatment regimens are prescribed in the real world, i.e. how clinicians behave in the absence of clear guidelines.

This observational study involves patients affected by non-valvular atrial fibrillation undergoing percutaneous coronary intervention (i.e. with a therapeutic indication for dual or triple antithrombotic therapy), to describe the real-world prescription model used in clinical practice and to analyze the results of therapeutic choices in terms of mortality, hemorrhagic and ischemic events.

Patients are enrolled within 7 days from percutaneous coronary intervention during their hospitalization period. During the enrolment visit (i.e. baseline, T0), all patients undergo a detailed assessment of their medical history related to the recent hospitalization, laboratory blood analysis, and data related to their cardiovascular risk factors. Follow-up visits will be performed at three months (T3) and twelve months (T12). During the follow-up visit, any ischemic/bleeding events, therapeutic changes, and laboratory blood analysis will be recorded.

Study Timeline

• Study Start: 2020-07-28
• Study First Submitted: 2024-01-25
• Study First Submitted QC: 2024-01-25
• Study First Posted: 2024-02-02
• Primary Completion: 2024-07-28
• Study Completion: 2024-07-28
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-19
• Last Update Posted: 2025-02-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 394

Inclusion Criteria

• Patient with non valvular atrial fibrillation with direct oral anticoagulants therapy
• Patient on antiplatelet therapy (acetylsalicylic acid and/or inhibitor of the P2Y12 platelet receptor)
• Patient hospitalized for percutaneous coronary intervention in the previous 7 days
• Age ≥18 years
• Estimated life expectancy ≥ 12 months
• Ability to give informed consent

Exclusion Criteria

• Patients who have contraindications to direct oral anticoagulants therapy
• Patients who are indicated for direct oral anticoagulants therapy for reasons other than non valvular atrial fibrillation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding	12 months	Incidence of major bleeding and clinically relevant non major bleeding

Secondary Outcome Measures

Name	Time	Method
Adverse events	12 months	Cardiovascular events, death

Trial Locations

Locations (1)

Istituti Clinici Scientifici Maugeri; 🇮🇹 Milan, Italy